Poland· PL-100475031
TECVAYLI
A teclistamab product containing teclistamabum, registered in Poland by Janssen-Cilag International N.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Teclistamab is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FX24 (teclistamab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Teclistamab · ATC L01FX24
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Teclistamabum
- Manufacturer
- Janssen-Cilag International N.V.
- Country
- Poland (PL)
- ATC code
- L01FX24
- ATC class
- Teclistamab
- Defined daily dose
- 15 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05413868121575
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Teclistamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTecvayli 10 mg/mlJanssen-Cilag International
- SwitzerlandTecvayli 30 mg/3 ml, InjektionslösungJanssen-Cilag AG
- CzechiaTECVAYLIJanssen-Cilag International N.V., Beerse
- SpainTECVAYLI 10 MG/ML SOLUCION INYECTABLEJanssen-Cilag International N.V
- IcelandTecvayliJanssen-Cilag International NV*
- NorwayTecvayliJanssen-Cilag International N.V.
- SwedenTecvayli 10 mg/ml Injektionsvätska, lösningJanssen-Cilag International NV
- FinlandTECVAYLIOrifarm Oy
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tecvayli
- Liechtenstein · Tecvayli
- Norway · Tecvayli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4f1d898d-c254-4f87-953d-e07b40ff5b4a GET /v1/drugs/4f1d898d-c254-4f87-953d-e07b40ff5b4a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "10 mg/ml",
"packaging": "05413868121575 ¦ Rpz ¦ EU/1/22/1675/001 ¦ 147349\n1 fiol. 3 ml",
"substance": "Teclistamabum 30 mg",
"common_name": "Teclistamabum",
"pl_product_id": "100475031",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about teclistamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.